DYADIC INTERNATIONAL, INC.

DYAI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017
Operating Activities
Net Income $-2.1M
Depreciation & Amortization
Depreciation
Amortization
Stock-Based Compensation $643.4K
Net Cash from Operating Activities $-1.7M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities $-812.1K
Financing Activities
Dividends Paid
Stock Repurchases $6.2M
Net Cash from Financing Activities $-6.2M
Net Change in Cash $-8.5M
Free Cash Flow
← Newer Page 2 of 2 Older →